Xspray Pharma Q4 2023: NDA-resubmission accepted by the FDA - Redeye
Redeye updates its outlook for Xspray following its Q4 report, and we highlight that the recently announced PDUFA-date at the end of July marks a significant catalyst for the stock.
ANNONS
Redeye updates its outlook for Xspray following its Q4 report, and we highlight that the recently announced PDUFA-date at the end of July marks a significant catalyst for the stock.